The above studies suggest that MCP-1 inhibition can restore glomerular barrier function by influencing macrophage CTSL secretion and reducing heparanase activation, highlighting the potential pathogenicity of CTSL released from infiltrated renal macrophages in DKD. Here, CCL2 is linked to diabetic kidney disease.